. The two most important lung complications in SSc are lung fibrosis, which reflects the tendency of SSc to cause scarring in the skin and internal organs, and pulmonary arterial hypertension (PAH), which reflects the cardinal proliferative vasculopathy that occurs in SSc 3, 4 . SSc can be divided into two major clinical subsets on the basis of the extent of skin fibrosis: limited cutaneous SSc (lcSSc; affecting the face, neck and distal limbs) and diffuse cutaneous SSc (dcSSc; affecting the proximal limbs, abdomen and chest). These two major subsets also differ in the associated frequency and pattern of different SSc-associated autoantibodies and key clinical characteristics 5 . The pathogenic mechanisms of lung fibrosis and PAH are complex and incompletely understood but involve interplay and crosstalk between the cellular constituents of the lung. These complications are probably triggered by lung injury or damage in the epithelial and parenchymal compartments (for lung fibrosis) or the endothelium and pulmonary vasculature (for pulmonary hypertension) (Fig. 1) . Strategies for managing lung fibrosis and pulmonary hypertension, especially PAH, have considerably advanced in the past few years. Major challenges in managing both conditions include the detection of patients with clinically meaningful disease, the identification of patients who are likely to bene fit from intervention and the formulation of an optimal management plan that includes the treatment goals, the choice and dose of treatments and the means for efficiently monitoring patients.
New developments in our understanding of the pathogenesis of lung fibrosis have led to pivotal clinical trials of historical treatments and novel therapies. The search continues for treatments that might be as effective but are safer than current therapies. Various targeted biologic therapies are being tested as one possible avenue. Likewise, the development of antifibrotic agents has made substantial progress. In addition, researchers are defining new tools for assessing the severity of lung fibrosis in SSc and the risk of progression, which should help improve the accuracy of treatment decisions.
In pulmonary hypertension, detecting patients with SSc at high risk of developing PAH, as well as differentiating patients with PAH from patients with other forms of pulmonary hypertension (including post-capillary disease), is challenging. Once a patient is diagnosed with PAH, the effects of relevant comorbidities, including other lung or heart complications, on the patient's disease are important to consider.
Major lung complications of systemic sclerosis
Results from new clinical trials into the treatment of lung complications in SSc have advanced practice and provide an evidence base to support current treatments. For both lung fibrosis and PAH, the concept of improving established disease and not just slowing progression is advancing. In this Review, we cover the major pulmonary aspects of SSc and discuss the current diagnostic approaches and treatment strategies.
Pathogenesis
Lung involvement in SSc is best defined in terms of extrapulmonary features (such as respiratory muscle weakness or skin fibrosis of the chest wall that might restrict breathing and includes pleural effusion) and intrapulmonary manifestations. The two major complications within the lung are lung fibrosis and pulmonary hypertension, although other processes involving the lung parenchyma can also develop (such as organizing pneumonia). Pulmonary vascular disease includes PAH and other forms of pulmonary vasculopathy such as thromboembolic disease and pulmonary veno-occlusive disease (PVOD). These forms of pulmonary vasculo pathy should be distinguished from post-capillary pulmo nary hypertension. These various lung complications can have shared underlying disease mechanisms (Fig. 1) .
Pathogenesis of lung fibrosis. Fibrosis is a general term describing the excessive formation of scarred or thickened tissue with excessive extracellular matrix in response to tissue damage, inflammation or as part of a specific process termed fibrogenesis in which activated fibroblasts or myofibroblasts produce excessive extracellular matrix. SSc-associated lung fibrosis probably shares common pathogenic mechanisms with other parenchymal lung diseases and with other fibrotic manifestations of SSc. Multiple cell types and mediators are implicated in lung fibrogenesis 6, 7 , including lung epithelial cells (pneumocytes), inflammatory cells of all immune lineages and mesenchymal cells (including lung fibroblasts and myofibroblasts) 7, 8 . Myofibroblasts are activated profibrotic contractile cells that resemble fibroblasts but are characterized by the expression of α-smooth muscle actin; myofibroblasts are central to the development of fibrotic lung pathology (Fig. 1) .
Some clues about SSc pathogenesis have emerged from gene expression profiling studies of lung tissue and cultured fibroblasts 8, 9 as well as other cells isolated from biopsy samples or obtained through bronchoalveolar lavage 10 , including lymphocytes, mononuclear cells and fibrocytes. Functional studies have confirmed that lung fibroblasts have a profibrotic phenotype in SSc 11 , and researchers have identified candidate pathways and regu lators, including transforming growth factor-β (TGFβ), CC-chemokine ligand 2 (CCL2) and IL-13, that enhance extracellular matrix production and increase contractility and myofibroblast differentiation [12] [13] [14] . Studies of epithelial and endothelial cells from the lung tissue of patients with SSc-associated lung fibrosis also suggest a role for endothelial-mesenchymal and epithelial-mesenchymal transition in fibrotic lung pathology 15, 16 , meaning that the pathogenic population of myofibroblasts has multiple potential lineages of origin that might contribute to excessive extracellular matrix deposition and obliteration of normal lung architecture. In addition, serum levels of IL-6, CCL2 and CXC-chemokine ligand 4 (CXCL4) are associated with the occurrence and/or progression of lung fibrosis in SSc, implicating these factors as potential markers or mediators of lung fibrosis [17] [18] [19] . As with other parenchymal lung diseases, environmental factors probably contribute to pathogenesis. In SSc, epithelial injury and damage resulting from aspiration or micro-aspiration are potentially involved in lung fibrogenesis. In one mouse strain that is genetically susceptible to lung injury, the introduction of a mildly acidic saline solution into the lungs caused fibrosis 20 . This finding is consistent with human studies that have demonstrated the presence of epithelial injury (as measured by serum levels of mucin 1 (MUC1, also known as KL-6) or clearance of aerosolized diethylenetriamine pentaacetate (DTPA)) 21 in patients with SSc. Other studies have linked lung fibrosis severity with oesophageal reflux severity in SSc 22, 23 . Epithelial injury might selectively activate profibrotic pathways including TGFβ signalling pathways, possibly via promoting conformational changes in the integrin-TGFβ complex. The involvement of epithelial injury and defective repair in lung fibrogenesis via increased TGFβ pathway activation is supported by the results from several relevant mouse models 24, 25 and occurs through local activation of TGFβ via integrin pathways or via postnatal activation of canonical receptor-mediated signalling.
Experimental findings of genetically modified mice with fibroblast-specific attenuation of TGFβ signalling further support a pivotal role for TGFβ signalling in the development of lung fibrosis 26, 27 . A subpopulation of resident lung fibroblasts is speculated to coordinate repair and be involved in the regulation of other fibrogenic cells that have migrated from the peripheral blood including fibrocytes 26, 27 . Other lineages such as endothelial cells and lung epithelial cell lineages might also contribute to the fibrogenic population of cells in SSc. In the past few years, researchers have attempted to confirm findings from mouse models in human tissue models or human skin ex vivo 28 . These studies suggest that chronic administration of bleomycin yields consistent results in mouse and human skin and support an important potential role for circulating fibrogenic cells in SSc-associated lung fibrosis 29 .
Key points
• lung complications are frequent in systemic sclerosis (SSc) and include lung fibrosis and pulmonary hypertension, which have a substantial effect on disease outcomes and are major causes of SSc-related death.
• Systematic evaluation of patients ensures that diagnosis of lung fibrosis and pulmonary hypertension is timely and permits treatment at the earliest possible stage.
• multiple licensed therapies exist for pulmonary arterial hypertension, and use of these agents alone and in combination has improved outcomes and survival in event-driven trials.
• There are no approved therapies for lung fibrosis, but treatment with immunosuppression seems beneficial in clinical trials and is recommended for appropriate patients with severe or progressive lung fibrosis.
Fibroblasts
Cells that produce extracellular matrix and that are activated inappropriately or excessively in fibrotic disease.
Myofibroblasts
Activated fibroblastic cells that have a contractile cytoskeleton that includes microfibrils containing α-smooth muscle actin.
www.nature.com/nrrheum Multiple cell types and mediators are probably involved in the pathogenesis of lung fibrosis and pulmonary arterial hypertension (PAH). For lung fibrosis, tissue damage initiated by epithelial injury or inflammation might result in a local environment within the lung parenchyma that leads to the generation and persistence of myofibroblasts. Accumulation of excess extracellular matrix and destruction of the lung structure in the absence of repair and regeneration can most often lead to a nonspecific interstitial pneumonia pattern of lung disease. In the pulmonary circulation, endothelial damage might promote a proliferative vascular response that includes multiple cell types and results in endoluminal lesions and medial wall thickening. Vascular fibrosis and perivascular inflammation can subsequently occur. The pathogenic processes that occur following epithelial injury (leading to lung fibrosis) and pulmonary endothelial injury (triggering PAH) seem to be shared. Hence, systemic sclerosis might be a susceptibility phenotype for these complications and other facets of the disease process, and autoimmune, genetic or environment factors might determine which of the potential manifestations are predominant. EMT, epithelial-mesenchymal transition; Endo-MT, endothelial-mesenchymal transition.
Circulating and local resident monocyte-macrophage lineages are emerging as potential key effector cells in SSc lung fibrosis 16, 30, 31 . Analysis of genes expressed in the skin that are associated with severity of lung fibrosis 32, 33 and a similar gene and protein analysis using a systems biology approach have contributed to a growing body of evidence implicating altered monocyte and macrophage function in the pathogenesis of SSc-associated lung fibrosis 34 . Genetic susceptibility might also be important in the development of lung fibrosis. A strong and consistent association exists between genetic risk factors (such as those identified by Immunochip analysis) and antinuclear antibody (ANA) patterns, providing support for a key role of the adaptive immune response in SSc pathogenesis 35 . Many genetic studies have been undertaken in SSc-associated lung fibrosis, and a growing number of candidate genes have been identified from association studies or direct sequencing [36] [37] [38] [39] . In general, immunologi cal or inflammatory candidates seem to be more consistently identified in independent cohorts than factors relating to fibrosis, although in a complex heterogeneous disease such as SSc, the genetic associations from single cohorts might shed light on candidate pathways or mediators involved in pathogenesis even if conventional genetic replications across cohorts are not possible. This heterogeneity might reflect gene-environment interactions, differences in cofactors and other genetic or epigenetic differences between different study cohorts. For example, the association of SSc and a polymorphism in CTGF was reported by two independent single-centre cohorts 40, 41 but not in another large multinational study population 42 . Findings from two meta-analyses support a role for this polymorphism in UK or Japanese populations but not in other populations 43 , which could explain previous negative results 42, 44 . Epigenetic factors are potential contributors to SSc fibrogenesis; for example, particular microRNAs, including miR-155, are associated with lung fibrosis 45 , and bromodomain inhibitors have potential antifibrotic effects in SSc lung fibroblasts 46 . Additional complex gene-environment interactions probably contribute to lung pathology in SSc; for example, experimental studies support a role for the microbiome, with early antibiotic exposure associated with increased susceptibility to experimental lung fibrosis in a mouse model of SSc 47 .
Pathogenesis of pulmonary hypertension. The development of both pulmonary hypertension and lung fibrosis in SSc have overlapping features. Vascular injury including pulmonary endothelial cell injury and endothelial dysfunction might be a key component in the development of both pathologies; vascular injury leads to an aberrant fibroproliferative or aberrant repair process that also results in an obliterative pulmonary vasculopathy 48 . SSc-associated PAH is histologically similar to idiopathic and hereditable PAH, with muscularization of intrapulmonary arterioles and medial thickening with perivascular inflammatory changes, although SSc-associated PAH has a lower prevalence of endothelial proliferative and plexiform lesions than other forms of PAH 49 . SSc-associated PAH might even be a phenocopy of heritable PAH. The TGFβ receptor family member bone morphogenetic protein receptor type 2 (BMPR2) is implicated in the pathogenesis of a number of forms of PAH, notably hereditable disease and idiopathic PAH; reduced levels of BMPR2 in the lung blood vessels are associated with structural changes in the lung 50 . Interestingly, mouse models of SSc that implicate endothelial injury as a trigger of SSc-associated PAH also point towards a possible defect in BMPR2 expression and function that could represent a unifying mechanism and potential susceptibility factor for several forms of PAH 51 . Hence, SSc might be a susceptibility phenotype for PAH, which would explain why the risk of developing PAH is highest in established disease and continues through the course of follow-up 52 . The mechanisms of PAH are complex and as with lung fibrosis probably involve multiple cell compartments that might contribute differently in different patients. Support for the role of immune cells in the development of SSc-associated PAH is emerging; on the basis of transcriptomic and serum analysis, macrophage or monocyte dysfunction, including M2 polarization, is associated with PAH development in SSc 53 . Endothelial-mesenchymal transition might also contribute to the fibroproliferative pathology seen in affected pulmonary vessels 54 .
Other relevant pathogenic mediators include cytokines such as IL-6 and proliferative factors such as platelet-derived growth factor (PDGF) or connective tissue growth factor (CTGF) that could be targeted with intracellular signalling inhibitors. The success of the antioxidant bardoxolone methyl in phase II trials of SSc-associated PAH points towards a possible role for cellular stress via mitochondrial dysfunction, oxidant stress and/or inflammation-induced damage in PAH pathogenesis. Studies implicate circulating adipsin (also known as complement factor D), an adipokine that also regulates activation of the alternative complement pathway, in SSc-associated PAH pathogenesis 55 . Some SScspecific genetic susceptibility loci for PAH have been described 56 and analysed 57 , although no major associations have emerged. Thrombosis, which is an important contributor to chronic thromboembolic pulmonary hypertension (CTEPH) pathogenesis, is also evident in some patients with SSc-associated PAH but not in patients with SSc without PAH (as observed using optical coherence tomography at initial time of diagnosis) 58 . Unfortunately, the risk to benefit ratio of anticoagulant use in patients with SSc-associated PAH is unfavourable, possibly because of the high frequency of gastrointestinal lesions in this population 59 . SSc-associated PAH might also share pathogenic mechanisms with other forms of pulmonary hypertension. Thus, factors that underlie other forms of pulmonary hypertension might be relevant. Hypoxia is a key driver of group III pulmonary hypertension. Likewise, cardiac involvement is important for determining the development of pulmonary venous hypertension (PVHT) or group II pulmonary hypertension. On the basis of histological analysis, SSc-associated PAH has been suggested to have components of PVOD, which could partially explain why some patients respond www.nature.com/nrrheum poorly to vasodilator therapy 60 . However, although PVOD is present in some patients with SSc-associated PAH on CT imaging, the overall frequency seems to be somewhat low 61 .
Assessment of lung involvement
Systematic approaches for screening and assessing patients with SSc for lung involvement are associated with increased ascertainment of major organ-based complications and improved long-term survival 62 compared with historic cohorts without regular screening. Thus, a comprehensive assessment at initial diagnosis followed by a regular systematic assessment of cardiorespiratory function is recommended for all patients with SSc 63 . This strategy is important for the management of lung disease, for a differential diagnosis and to help evaluate the treatment response, which can be challenging owing to the multiple mechanisms of disease and comorbidity. The investigation of lung involvement in SSc generally starts with a clinical examination and simple imaging such as chest radiography followed by formal lung function testing and CT imaging. Lung function tests include measures of lung volume such as total lung capacity and forced vital capacity (FVC) and measures of gas exchange determined by the diffusing capacity for carbon monoxide (DLco), which can be expressed for the whole lung or corrected for the measured alveolar volume (termed the gas transfer coefficient). CT imaging is the best way to evaluate lung fibrosis, whereas a right heart catheterization is required for a formal diagnosis of pulmonary hypertension, even if it is already suspected on the basis of clinical features or echocardiography.
Exertional dyspnoea is a common presenting symptom in patients with either pulmonary fibrosis or pulmonary hypertension. Worsening exertional dyspnoea in patients with SSc is an important symptom that should prompt further evaluation for lung complications. However, the differential diagnosis for patients with SSc and dyspnoea is broad, reflecting the multiplicity of disease-related mechanisms and other confounding factors that contribute to dyspnoea (Box 1).
Loss of exercise tolerance in patients with SSc is commonly multifactorial. The cumulative effect of SSc and comorbidities on exercise capacity has been quantified using the Frailty index, which reflected the severity of dyspnoea 64 . Determining the contribution of cardiopulmonary limitation to exercise intolerance is difficult because of two important confounding factors: anxiety and fatigue. In patients with anxiety, hyperventilation might cause dyspnoea or heighten dyspnoea severity, especially in well-informed patients who are sensitized to the dangers of cardiopulmonary involvement in SSc. Fatigue, a frequent source of disability in patients with SSc 65 , might manifest as exercise intolerance and the distinction between limiting fatigue and limiting dyspnoea is often difficult to make.
In severe pulmonary fibrosis or PAH, prominent exercise intolerance can usually be confidently ascribed to lung involvement. However, in the remaining patients presenting with dyspnoea but without prominent exercise intolerance, a form of exercise testing (the six-minute walk test) enables the assessment of cardiopulmonary function (using the point of oxygen desaturation as a measure of exercise tolerance), and this test might identify other causes such as cardiac dysfunction 66, 67 . Diagnosis of lung fibrosis. All patients with SSc should be thoroughly examined for the presence of lung fibrosis at initial presentation and during follow-up. Regular assessment increases the chance of detecting lung fibrosis early, thus enabling an early intervention. Currently, CT imaging is the best tool for detecting lung fibrosis and enables the pattern and extent of disease to be determined 68 . In addition, CT imaging seems to be more reliable than using lung function tests to screen patients. The normal limits for lung function tests range from 80% to 120% of the average value for a person of the same sex, weight and height (as predicted by a computerized lung function test algorithm), and this wide range means that many patients with pulmonary fibrosis do not show overt impairment at initial screening 69 . However, lung function tests should still be performed at baseline and are the cornerstone of longitudinal follow-up 52 .
Other methods for assessing patients with SSc are available, such as routine chest radiography, exercise tolerance testing and dyspnoea scores, but these methods have limited use for detecting early lung fibrosis. Routine chest radiography lacks the sensitivity for detecting lung fibrosis but might be performed to assess other pathologies. Measures of exercise tolerance also have limited sensitivity, probably owing to the confounding effects of extrathoracic manifestations of SSc 70 , although measuring exercise tolerance might be valuable in the exclusion of clinically meaningful disease once lung fibrosis has been identified. Likewise, dyspnoea scores are of limited use in the diagnosis of lung fibrosis but are valuable for trials or the longitudinal follow-up of patients 71 .
Although researchers have developed risk scores for the prediction of lung complications in patients with SSc (as discussed in the next section), at present, a systematic approach for the screening and follow-up of patients with SSc is important and justified by the high overall risk of developing severe lung fibrosis 52 .
Screening and diagnosis of pulmonary hypertension.
The high risk of pulmonary hypertension in SSc, and the major effect that pulmonary hypertension has on survival and quality of life 72 , justifies the screening of patients. Hence, screening patients with SSc for pulmonary hypertension is recommended in clinical practice, and several screening approaches have been developed. Patients should be screened for pulmonary hypertension at least once a year, as early diagnosis can enable early treatment that could improve the long-term outcome.
One of the first advocated screening approaches, developed as a result of the French ItinérAIR-Sclérodermie study, used echocardiographic thresholds to prompt routine right heart catheterization 73 . In the past few years, other approaches have been developed that integrate lung function, echocardiography and the presence of other relevant markers such as N-terminal probrain natriuretic peptide (Nt-proBNP) 74 . Results from comparative studies suggest that these screening tools all
Lung function testing
A collective term for the physiological measurement of lung volume, airways resistance and gas exchange in the lungs.
Exertional dyspnoea
Subjective breathlessness that occurs on exertion and is a cardinal feature of substantial lung complications including lung fibrosis and pulmonary hypertension.
Dyspnoea
Breathlessness that is a major symptom of lung complications in systemic sclerosis but that also has other potential causes including cardiac disease, anaemia and deconditioning.
NATuRe RevIewS | RHEuMATOlOgy R e v i e w s volume 14 | SePTemBeR 2018 | 515 perform well in clinical practice 71, 75, 76 . For example, one approach is to use the DETECT algorithm, an evidencebased tool that integrates non-invasive clinical and laboratory variables and echocardiography, to assess the risk of PAH 77 ( Fig. 2) . The DETECT algorithm was developed in a large cross-sectional cohort 77 to integrate noninvasive tests and minimize missed diagnoses of PAH. When considering lung function tests, it is important to consider that concurrent emphysema might reduce the utility of measuring gas exchange (DLco) in patients for screening, as it might increase FVC and diminish DLco independent of pulmonary hypertension 78, 79 . The DETECT cohort included patients with mild PAH, and specific determinants of PAH progression have been elucidated using data from this cohort 80 and align with variables identified in other cohorts such as Nt-proBNP levels and low DLco 52, 81, 82 . The DETECT algorithm first examines six variables (FVC, telangiectasia, anticentromere antibody positivity, electrocardiogram right axis deviation and serum levels of Nt-proBNP and urate) to generate a score. If this score is above a defined threshold, an echocardiogram is recommended, and various echocardiographic measures (the tricuspid regurgitant jet velo city and right atrial area) are used to generate the final DETECT score. If the DETECT score surpasses a defined threshold, a right heart catheterization is recommended, as the patient has a considerable risk of having PAH. The DETECT score was devised using data from patients with SSc who had a disease duration of >3 years and a predicted DLco of <60%, and so this approach is best suited for use in such patients. Otherwise, echocardiography, lung function testing and measurements of Nt-proBNP, together with clinical assessment, are the main tools for assessing the risk of PAH.
Defining the presence of other connective tissue diseases (CTDs) in patients with SSc-associated pulmonary hypertension is important, as patients with overlap features might benefit from concurrent immunosuppression 83 . All screening programmes can help identify patients with borderline elevation of mean pulmonary arterial pressure, which is associated with distinct characteristics 84 and a high risk of developing PAH during follow-up, and so such patients need to be carefully monitored 85, 86 . Defining the presence of increased pulmonary artery wedge pressure in SSc-associated PAH is also important, as this feature can affect the disease outcome and reduce the response to PAH-specific therapy 84 .
Mixed phenotypes with elements of lung disease and possible post-capillary components probably also occur and need careful evaluation and treatment to ensure that treatable precapillary components are defined and addressed 87 . In a 2017 study, patients with SSc-associated PAH who had a preserved pulmonary vascular bed (as assessed using optical coherence tomography at right heart catheterization to directly image the intrapulmonary vessel wall thickness and structure) showed a better response to PAH-specific treatment than those patients with a damaged pulmonary circulation 58 . This finding is in line with other outcome studies suggesting that milder disease is associated with better outcomes than severe disease and fits with the current 2015 recommendations from the European Society of Cardiology and the European Respiratory Society for risk assessment and treatment 88 . Exercise testing could be an additional useful screening test for pulmonary hypertension, but other musculoskeletal and extrathoracic manifestations might confound results 89, 90 . More comprehensive risk prediction scores for pulmonary hypertension are in development, but the value of these scores is presently limited, and they require validation. Identifying patients who have a very low risk of developing PAH, and hence who do not require intensive screening, can be more important than identifying those at high risk. MRI is emerging as a non-invasive tool that might help stratify patients and diagnose the presence of pulmonary hypertension but is not yet used in routine assessment of PAH-associated SSc 91 . Autoantibodies, especially anti-U3 ribonucleoprotein (RNP), anticentromere antibodies, anti-RNA polymerase III and anti-Th/To RNP antibodies, are helpful in defining increased or reduced risk of PAH and hence are helpful in risk stratification 92, 93 . The extent and severity of concurrent lung fibrosis are important, as they might suggest a diagnosis of group III pulmonary hypertension and need to be carefully defined 94 .
Box 1 | Potential causes of dyspnoea in patients with systemic sclerosis
Parenchymal lung disease In addition to typical systemic sclerosis (SSc)-associated interstitial lung disease, some patients with overlap syndromes might present with patterns of lung involvement associated with other autoimmune rheumatic diseases 67 , such as organizing pneumonia (a frequent feature in myositis) and airway involvement (seen in rheumatoid arthritis and Sjögren syndrome) 67 .
Respiratory comorbidities
Comorbidities including smoking-related emphysema, infection and pulmonary thromboembolism can cause dyspnoea.
Pulmonary vasculopathy
Pulmonary arterial hypertension (PAH) can present with exertional dyspnoea. In some patients, pulmonary vascular disease is not sufficiently severe to manifest as PAH at rest but can cause exertional dyspnoea owing to a loss of pulmonary vascular reserve 71 .
Cardiac involvement
Dyspnoea might be caused by systolic or more commonly diastolic dysfunction, rate or rhythm disturbances 5 or pericardial effusion. Cardiac involvement is frequent in SSc but can be challenging to diagnose and is not always symptomatic 66 .
Cardiac comorbidities
Coronary heart disease and valvular heart disease (especially aortic stenosis) can cause dyspnoea and might be associated with angina, but dyspnoea without concurrent angina might reflect otherwise unsuspected cardiac comorbidity in some patients.
Anaemia
This condition might arise from a variety of mechanisms and can cause dyspnoea and might also aggravate other manifestation such as PAH
.

Arthritis
Arthropathy, owing to either autoimmune disease or concurrent osteoarthritis, can, in isolation, cause exertional dyspnoea because of the increased work of locomotion.
Muscle involvement
Peripheral muscle limitation because of autoimmune muscle involvement is an often-underestimated contributor to exercise limitation 167 .
Conditioning
Cardiorespiratory and musculoskeletal conditioning are common causes of subjective exertional dyspnoea in SSc 5 , which might be amplified if loss of fitness is associated with substantial weight gain.
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Classification of lung involvement Classification of interstitial lung disease. The classification of interstitial lung disease (ILD) is complex, but historically this disease has been subclassified on the basis of histological patterns observed in lung biopsy samples (Fig. 3) . The most common histological subtype that occurs in patients with SSc is nonspecific interstitial pneumonia (NSIP) 67 . Although a subclassification of NSIP was originally based upon histological patterns, correlations between lung biopsy findings and CT findings mean that patients with NSIP can be identified with high confidence using CT imaging 68 . NSIP can be further subdivided into reversible cellular NSIP and irreversible fibrotic NSIP subtypes on the basis of the degree of inflammation present in the lung 95 . A minority of patients with SSc has another histological pattern referred to as usual interstitial pneumonia (UIP), which is the defining histological pattern of idiopathic lung fibrosis. In idiopathic lung fibrosis, the UIP pattern is associated with much faster progression and worse survival than the NSIP pattern; however, the major prognostic distinction observed between NSIP and UIP patterns of disease (histologically or by CT imaging) in idiopathic lung fibrosis does not apply to SSc-associated ILD. The outcome of SSc-associated ILD is much better than idiopathic pulmonary fibrosis 96 ; mortality is similar for patients with SSc-associated ILD and an NSIP pattern and those patients with a UIP pattern 95, 96 . Some patients with SSc can also have other forms of ILD. For example, fibroelastosis is increasingly being recognized as a feature of CTD-associated ILD, can occur in association with pleural abnormalities and resembles idiopathic pleuroparenchymal fibroelastosis (a rare form of ILD with a poor prognosis). This form of ILD might be more progressive than other forms of SSc-associated ILD 97 . Currently, the precise frequency and clinical relevance of fibroelastosis in SSc-associated ILD are unknown 98 . Patients with overlap SSc, which This schematic is an example of one approach for diagnosing and screening patients with pulmonary hypertension and is in line with current recommendations for the diagnosis and management of such patients 71, 76 . All patients with systemic sclerosis (SSc) should have an initial assessment looking at clinical features, lung function (including measures of the diffusing capacity for carbon monoxide (DLco)) and transthoracic echocardiographic findings. The abundance of N-terminal pro-brain natriuretic peptide (Nt-proBNP) should also be measured. For patients with a DLco <60% and disease duration of >3 years, the DETECT score can be calculated 77 . These tests are repeated annually in all patients, and if a patient develops clinical features suggestive of new pulmonary hypertension, these tests are repeated more often. If the results (from either the transthoracic echocardiographic findings, pulmonary function tests or DETECT score) exceed defined thresholds, right heart catheterization should be performed to confirm a diagnosis of pulmonary hypertension. A diagnosis of pulmonary arterial hypertension (PAH) requires a low pulmonary arterial wedge pressure (PAWP) and the absence of major lung fibrosis (which would otherwise be classified as group III pulmonary hypertension). FVC, forced vital capacity ; mPAP, meaning resting pulmonary arterial pressure; PVR , pulmonary vascular resistance; WU, Wood units.
represents up to 20% of patients with SSc 99 , exhibit clinical features of the overlapping disease (for example, myositis or systemic lupus erythematosus (SLE)), which can include parenchymal lung disease. For example, myositis is associated with organizing pneumonia, and SLE is associated with shrinking lung syndrome or lymphocytic interstitial pneumonias 67 . Analyses of patient cohorts in the past few years have provided further insights into the timing and frequency of clinically important lung fibrosis development in SSc. Up to half of patients with dcSSc eventually develop severe lung fibrosis, and many of these patients develop this complication within the first 3 years following diagnosis and can have considerable lung involvement at initial presentation 52, 100 . This finding has important implications for treatment strategies aiming to prevent or attenuate worsening of disease. Overall, the frequency of lung fibrosis in patients with lcSSc is approximately half that of those with dcSSc (meaning that approximately one-quarter of patients with lcSSc is affected). Lung fibrosis is associated with different patterns of ANAs, in particular anti-DNA topoisomerase 1 (TOP1) antibodies. Approximately two-thirds of patients who are positive for the anti-TOP1 antibody ultimately develop moderate to severe ILD 5 . Other less common ANAs such as anti-U11/U12 RNP antibodies or anti-Th/To RNP antibodies are also associated with lung fibrosis 101 . Interestingly, the presence of anticentromere antibodies or anti-RNA polymerase III antibodies seems to be negatively associated with severe lung fibrosis 100, 101 , and so presence of these antibodies can be used to identify patients at lower risk in clinical practice and encourage further investigation of respiratory symptoms.
Stratification by lung fibrosis severity. In clinical practice, the most important aspect for managing lung fibrosis in patients with SSc is identifying those patients with severe disease or at risk of disease progression. By studying the factors associated with disease progression in well characterized cohorts, researchers have defined several key risk factors for developing severe lung fibrosis 52 , which can be used in clinical practice (Box 2). The most important of these factors is the extent of disease severity, particularly in patients in the early stages of SSc.
The importance of determining lung fibrosis severity has led to the development of a simple staging system that incorporates CT assessment and measures of FVC. In practice, with this staging system, patients are first stratified into groups on the basis of whether they have clearly mild or extensive fibrosis (<20% lung involvement or >20% lung involvement, respectively, by high-resolution CT). In patients for whom the extent of fibrosis is indeterminable by CT imaging, they are instead stratified into these groups on the basis of FVC measurements (>70% for mild fibrosis and <70% for extensive fibrosis) 102 . A designation of mild or extensive fibrosis by this staging system is associated with symptoms of dyspnoea and impaired exercise capacity 103 . This staging system can also reportedly predict an increased risk of considerable future decline; for example, >20% lung involvement is associated with an increased risk of decline (as assessed by lung function tests) and decreased survival 104 . Other staging systems have also been suggested that are based on the analysis of large SSc cohorts 52 or clinical trial data sets 105, 106 and include features (such as arthritis) that might reflect clinical The most common histological pattern of lung fibrosis in SSc is nonspecific interstitial pneumonia (NSIP), which might be mild (part a) or extensive (part b); NSIP is characterized by relative preservation of lung architecture and often a homogeneous 'ground glass' change within the lungs on CT imaging (GG arrow). NSIP might have cellular or fibrotic subtypes. By contrast, compared with NSIP, the less common usual interstitial pneumonia (UIP) pattern of fibrosis (part c) has a much more altered architecture, a more variable severity of fibrotic lesions and a less homogeneous pattern with dense fibrosis and cystic changes, termed honeycombing (HC arrow). Pulmonary hypertension (part d) is characterized by enlargement of the pulmonary artery on CT imaging (PA arrow). A designation of pulmonary arterial hypertension (PAH) can be made if only mild lung fibrosis is present, as otherwise a classification of group III pulmonary hypertension is made. It is also important to note whether CT features of pulmonary veno-occlusive disease are present, such as septal lines, nodules or lymphadenopathy (not shown).
subtypes of SSc associated with a high risk of developing fibrosis 107 . Other factors that potentially predict future decline include markers of epithelial damage, such as serum levels of MUC1 and DTPA clearance, and circulating markers, such as CXCL4 and IL-6, although IL-6 is only predictive for patients with mild lung fibrosis 17, 108 . At present, all these measures are useful in only research settings pending further validation and standardization. In the future, composite markers that incorporate clinical and laboratory measures will probably be developed.
New approaches that use computer-assisted quantification of lung fibrosis are being developed 109, 110 and might offer further insights into disease progression and the refinement of staging systems in the future. As outlined above, baseline tests including CT imaging, lung function tests, ANA testing and the assessment of clinical features facilitate the stratification of individuals at high risk of developing severe lung disease for whom treatment is a high priority. Such approaches are especially useful in planning treatments such as haematopoietic stem cell transplantation (HSCT), which is associated with a high risk of treatment-related mortality but also long-term benefits such as increased survival 111 . New data suggest that in patients with extensive lung fibrosis (as designated by the severity staging system) 112 , serial lung function testing can be used to monitor disease progression and predict mortality; for example, a drop in FVC of >10% at 12 months is the strongest single predictor of mortality. Additionally, a 5-9% decline in FVC alongside a 15% fall in DLco at 12 months is also predictive of diseaseassociated mortality. These thresholds might be useful in the evaluation of treatment responses, making treatment decisions and identifying patients for inclusion (or exclusion) in clinical trials 109 . Change in lung function, assessed by a fall in FVC, is an important component of the newly developed composite response index for SSc clinical trials 113 , and a decrease in lung function is associated with worse outcomes 114 . Finally, as discussed above, particular ANAs are also associated with an increased or decreased risk of lung fibrosis 100, 101 .
Classification of pulmonary hypertension. The classification of pulmonary hypertension in SSc follows that of pulmonary hypertension associated with other diseases, and it is important to consider the multiple ways in which pulmonary hypertension can develop. Pulmonary hypertension is conventionally divided into five groups on the basis of clinical and pathobiological features (TABlE 1) . Overall, PAH (classified by the WHO as group I) is probably the most frequent form of pulmonary hypertension in SSc, but mixed forms (such as pulmonary hypertension with lung fibrosis and cardiac involvement) also exist. More than half of patients with SSc-associated pulmonary hypertension have PAH, but many patients have post-capillary pulmonary hypertension (WHO group II) or pulmonary hypertension associated with lung fibrosis or hypoxia (WHO group III) 52 . Pulmonary hypertension associated with lung fibrosis is generally defined as lung fibrosis affecting >20% of the lung volume, although precise estimates of the extent of lung fibrosis can be challenging in routine clinical practice 115 , and fibrosis can be exacerbated by the coexistence of emphysema 116 . In addition, some patients have concurrent PVOD (WHO group I′) or CTEPH (WHO group IV). The incidence rate of pulmonary hypertension of any form is approximately 1-2% per year in patients with SSc 52 . However, the frequency of pulmonary hypertension varies across different reports depending upon the duration of follow-up; the frequency might be 5% for a cohort with an average disease duration of 5 years, 10% for a disease duration of 10 years and 15% for a disease duration of 15 years 52 . This increase in frequency differs from other complications of SSc, such as renal crisis, that generally occur in early disease and is consistent with SSc representing a susceptibility phenotype for the development of pulmonary hypertension.
Treatment approaches
Treatment approaches for lung fibrosis. Immunosuppression remains the cornerstone for treatment of SSc-associated lung fibrosis. The benefits of immunosuppression are largely supported by findings from observational and retrospective studies 116, 117 . However, limitations of the open-label and retrospective design of most studies underpin the need for prospective randomized studies. A small number of prospective clinical trials have been performed and show immunosuppression has beneficial effects. The most notable of these studies is the Scleroderma Lung Study I (SLS I), which compared oral cyclophosphamide over 12 months with placebo 118 . In this study, oral cyclophosphamide was efficacious but had only a marginal treatment benefit and was associated with substantial toxicity. However, the fact that the benefit observed was only small reflected the inclusion of many patients with mild non-progressive lung disease, whereas post hoc sub-analyses suggested that in extensive disease, cyclophosphamide therapy had major benefits in preventing disease progression on the basis of results from lung function testing. The results of a 2-year follow-up study suggested that the benefit of oral cyclophosphamide continued to 18 months (the placebo subtracted difference at 18 months was 7%) but was attenuated by 24 months 119 . The Fibrosing Alveolitis in Scleroderma Trial (FAST) trial had a similar design to the SLS I trial but investigated 6 months of intravenous cyclophosphamide followed
Box 2 | Severe lung fibrosis risk factors
• Diffuse cutaneous systemic sclerosis 50 • less than 3 years disease duration 50 • Severe gastro-oesophageal reflux 22, 23 • The presence of antinuclear antibodies (in particular, anti-DNA topoisomerase 1 antibodies but also anti-Th/To ribonucleoprotein (RNP) antibodies or anti-u11/u12 RNP antibodies) 94 • A 'severe' score by the uK-RSA staging system 96 • Declining lung function 50 • evidence of epithelial damage (for example, elevated mucin 1 levels or fast diethylenetriamine pentaacetate clearance) 25 RSA, Raynaud's and Scleroderma Association.
NATuRe RevIewS | RHEuMATOlOgy by oral azathioprine. After 12 months, the benefits of this treatment were no different from placebo, although FVC showed a trend towards improvement in the treatment group compared with the placebo group that did not reach statistical significance 120 . In the Scleroderma Lung Study II (SLS II), mycophenolate mofetil (MMF) was as efficacious as oral cyclophosphamide in improving cough-specific measurements 121 , which was also observed when the data from both SLS studies were combined to include the placebo control from SLS I 122 . However, the tolerability of MMF was superior to cyclophosphamide, and MMF is now used as a first-line treatment in most centres 123 . The optimal dose of MMF for the treatment of SSc-associated ILD is probably 3 g daily, which was the target dose in the SLS II trial, although for patients who struggle to tolerate 3 g daily, 2 g daily might be considered. Further support for immunosuppression in SSc lung fibrosis comes from the American Scleroderma Stem Cell versus Immunosuppression Trial (ASSIST) 124 , the Autologous Stem Cell Transplantation International Scleroderma (ASTIS) 111 trial and, in 2018, the Scleroderma: Cyclophosphamide or Transplantation (SCOT) study 125 , which all compared intravenous cyclophosphamide with HSCT. In all three studies, HSCT was superior to cyclophosphamide therapy alone. However, the transplant-related mortality with HSCT was lower in the SCOT study than in the larger ASTIS trial. The SCOT study had a focus on lung fibrosis outcomes and yielded some impressive apparent improvements in established lung fibrosis (on the basis of computerassisted quantitative CT analysis) that point towards potential reversibility of lung fibrosis. However, HSCT remains a major undertaking, and potential transplantrelated mortality means that patients should be carefully selected for therapy, which emphasizes the value of staging or stratifying patients with SSc so that this therapy can be considered at a time when it might be best tolerated.
Although the SCOT study highlights the potential benefit of HSCT in treating SSc lung fibrosis, development of a similarly beneficial but less toxic treatment is necessary. Such a need is providing impetus for clinical trials that test biologic therapies or the use of new agents in combination with immunosuppression such as MMF or B cell depletion with rituximab 126 . For lung fibrosis, approaches such as IL-6 receptor (IL-6R) blockade can alter markers of fibrogenic macrophage differentiation or fibroblast activation 127 , and tocilizumab (an IL-6 inhibitor) is being further tested in ongoing clinical trials of SSc 128 . The role of the adaptive immune compartment in SSc lung fibrosis development is supported by studies of lymphocytes isolated from bronchoalveolar lavage fluid 10 that show markers of T cell activation 10 and the association of lung fibrosis with specific antibody reactivities 5, 129 . Thus, both T cell and B cell lineages might be relevant in lung fibrogenesis, which could explain the apparent benefit of immunosuppressive therapies in some patients 130 . For example, B cell depletion is effective in the treatment of some patients whose disease is refractory to other therapies, providing strong support for the contribution of B cells to the pathogenic microenvironment in SSc-associated lung fibrosis 131 .
Emerging clinical trials undertaken to test novel therapies include blockade of TGFβ 132 and its activation by epithelial αν integrin 133 , the IL-13-IL-4 axis and IL-4 (rEF.
134 ). In addition, two antifibrotic agents that can retard disease progression in idiopathic pulmonary fibrosis are currently undergoing evaluation in SSc-associated ILD: pirfenidone and nintedanib. Pirfenidone has already been evaluated in a small phase II study (LOTUSS) 135 , and the Scleroderma Lung Study III (SLS III) trial comparing MMF combined with pirfenidone treatment and MMF treatment alone is ongoing 136 . A large phase III trial investigating the safety and efficacy of nintedanib in SSc-associated lung fibrosis is ongoing 137, 138 . However, trials of lung fibrosis in SSc are challenging, and some studies have failed to recruit enough patients 139 or have had unequivocally negative results 140, 141 . In addition to immunosuppression for patients with extensive fibrosis or those predicted to be at risk of lung disease progression, other general measures for the treatment of SSc-associated lung fibrosis include vigorous management of gastro-oesophageal reflux 142 . Combinations of antacids (acid suppressive agents) and prokinetics, as well as simple lifestyle measures, are used in the treatment of gastro-oesophageal reflux. Oxygen therapy can also be useful for reducing exertional dyspnoea, and patients with severe lung disease might benefit from long-term, low-dose oxygen therapy to reduce the risk of developing secondary pulmonary hypertension (WHO group III). Oxygen therapy should be administered following general respiratory practice guidelines. Another important treatment approach in SSc-associated lung fibrosis is the management of infection. Prophylactic antibiotics should be considered for preventing community-acquired infection in patients reporting frequent lower respiratory tract infections and for preventing opportunistic infections such as pneumocystis in patients receiving long-term intensive immunosuppression 142 .
Treatment approaches for pulmonary arterial hypertension. Substantial advances in the management of PAH have been made over the past two decades, especially regarding oral therapies and the growing evidence base for the use of drug combinations 143 . Therapies have progressed from a time when only intravenous epoprostenol was available 144, 145 and outcomes were very poor to the current availability of multiple licensed treatments that can be used in combination (TABlE 2) . The early studies that led to the licensing of various PAH therapies, including bosentan and sildenafil, focused on short-term gains in exercise capacity; in these studies, the response of patients with SSc-associated PAH or CTD-associated PAH was often less efficacious than that of patients with other forms of PAH, although most treatments seem to result in meaningful benefit in the majority of patients with SSc-associated PAH [146] [147] [148] [149] . However, evidence in clinical practice suggests that these therapies have long-term benefits in SSc-associated PAH 142 , which is supported by key event-driven clinical trials published in the past 3 years [150] [151] [152] : the Study with an Endothelin Receptor Antagonist in Pulmonary 147, 148 , whereas the nitric oxide pathway (which mediates vasodilation through soluble guanylate cyclase) is probably a protective factor; soluble guanylate cyclase stimulators and inhibitors of PDE5 (an enzyme that breaks down guanylate cyclase) have shown some promise in the treatment of SSc-associated PAH 143 . Similarly, prostacyclin-dependent pathways are protective, and defects in these pathways might be important in pathogenesis 144 . The effectiveness of combination therapies, such as ambrisentan and tadalafil, suggests that multiple pathways and mediators are involved in the development of PAH in SSc 153 . All the pivotal trials of new PAH treatments over the past few years have included considerable numbers of patients with CTD-associated PAH or SSc-associated PAH, which has enabled subgroup analyses and helped to establish licensed drugs for PAH in SSc (TABlE 3) . The findings of these trials generally support the efficacy of specific licensed PAH treatments in PAH-associated SSc and are in line with emerging registry and retrospective cohort data 59 . The results of the three large, long-term, event-driven trials (SERAPHIN, GRIPHON and AMBITION) were positive and suggest that these treatments are also efficacious in patients with CTDassociated PAH, which is in line with the efficacy observed in the overall cohort that included patients with idiopathic or heritable PAH [150] [151] [152] 154, 155 . Studies of riociguat (a soluble guanylate cyclase stimulator) have had similarly encouraging results 156 , including the phase III trial that examined exercise capacity (that is, the six-minute walk test distance) as a primary end point; although, in this trial the response of patients with CTD-associated PAH or SSc-associated PAH was less overall than for patients with idiopathic PAH or the overall cohort 156 . Evidence-based recommendations are available for the treatment of pulmonary hypertension 88 and SSc-associated PAH 63 . Current recommendations support an aggressive use of combination treatments in patients with SSc at high risk of PAH 88 , which is now recommended by most expert centres. Patients with mild PAH or those patients with mixed pulmonary hypertension phenotypes might require less aggressive treatment, but formal evidence to support this notion is lacking. Emerging evidence from cohort studies supports the beneficial effects of intensive combination therapy in the most severe cases of SSc-associated PAH 154, 155, 157 .
The presence of cardiac disease or lung fibrosis is an important consideration in SSc-associated PAH, as these pathologies might occur concurrently, potentially resulting in a phenotype with a mixed aetiology that can affect the outcome and treatment response. For example, pulmonary vasodilators might be disadvantageous if they worsen the ventilation-perfusion ratio in pulmonary hypertension associated with lung fibrosis and detrimental in patients with a degree of post-capillary pulmonary hypertension owing to cardiac involvement. However, data from the GRIPHON study and other emerging data suggest that some patients with predominantly group I pulmonary hypertension but also elements of group II would benefit from PAH-specific treatments. The occurrence of PVOD and the risks associated with PVOD are also important to consider. PVOD occurring in SSc might be a mixed phenotype rather than a pure form of PVOD and could possibly respond to careful use of vasodilators 61 . Patients with complex forms of pulmonary hypertension should be managed by experts in SSc and experts in pulmonary hypertension collaboratively in specialist units to ensure that they receive optimal treatment.
Role of lung transplantation. Lung transplantation is a potential treatment option for some patients with SSc who have pulmonary hypertension or lung fibrosis. However, choosing whether to use this treatment is difficult, as lung transplantation is associated with a high frequency of relevant comorbidity including gastro-oesophageal reflux disease 158, 159 . Challenges related to previous treatment, steroid use and gastrooesophageal reflux are important to consider, as they might affect post-transplant complications and outcomes 160 . However, case series from the past decade suggest that transplantation has favourable outcomes in many patients with SSc and that long-term survival is comparable to that observed in patients with other multisystem diseases; hence, for some patients with SSc, heart, lung or combined transplantation is an important therapeutic option 161, 162 .
Conclusions
In this Review, we highlight the ongoing challenges of lung complications in SSc but also provide clear evidence of the changing landscape in terms of understanding pathogenic mechanisms, assessing patients and providing treatments that affect outcomes 163 . The timing and frequency of lung fibrosis and pulmonary hypertension in SSc indicate that both complications are important and somewhat frequent. An increasing understanding of pathogenic pathways means that the expanding number of biologic or synthetic agents that target specific pathways or mediators can be tested; furthermore, a better understanding of clinical trial design for lung fibrosis and PAH will ensure that the data obtained are robust and reliable. The situation is considerably more positive than a decade ago, and tangible progress will hopefully be made over the next few years. The ultimate test will be increasing long-term survival with better quality of life for patients with SSc, as observed after autologous stem cell transplantation 125 . NATuRe RevIewS | RHEuMATOlOgy Thus, despite the challenges of SSc, there is reason to be optimistic because an unprecedented number of drugs for targeting lung and skin involvement in SSc, including treatments that might target fibrosis in both sites, are being tested in clinical trials. Moreover, as the cost of PAH therapies decreases owing to generic formulations becoming available, opportunities will arise to implement combination treatment at an early stage of disease. Identification of patients with a poor prognosis at an early stage of disease will enable better targeting of treatment and might start to diminish the high mortality seen in patients with SSc 164, 165 . Highquality recommendations and guidelines are now available 63, 166 that provide a roadmap for best practice and will undoubtedly be further updated as new evidencebased treatments for lung disease emerge. The future is bright, as better tools for screening and diagnosis are being developed and a greater understanding of fundamental pathogenic mechanisms and identification of new potential therapeutic targets are being unveiled. Treatments for established lung complications are now available, and various others are in clinical trials, so that treatment approaches that prevent the progression of fibrosis and pulmonary hypertension will likely soon emerge, as will better ways to predict those at risk of major lung complications.
